Clinical trialNCT04495179CompletedPhase 2Interventional

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

SponsorAstraZenecaEnrollment30Progressive Metastatic Castrate-Resistant Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Christopher J Sweeney, MBBS
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Research Site
Brasschaat, Belgium
Research Site
Ghent, Belgium

France

Research Site
Bordeaux, France
Research Site
Villejuif, France

South Korea

Research Site
Goyang-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea

Spain

Research Site
Barcelona, Spain
Research Site
Barcelona, Spain
Research Site
Hospitalet deLlobregat, Spain
Research Site
Madrid, Spain

United States

Research Site
Sacramento, California, United States
Research Site
Tampa, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
St Louis, Missouri, United States
Research Site
Winston-Salem, North Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AZD4635Cabazitaxel →Durvalumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Aug 2020
Primary completion: 1 Nov 2021
Completion: 8 Aug 2022
Last update posted: 9 Aug 2023
Registered enrollment: 30
Registry id: NCT04495179

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-000209-10

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.